David Sidransky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11406539/publications.pdf

Version: 2024-02-01

2571 1799 45,049 427 103 195 citations h-index g-index papers 430 430 430 39634 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	A robust and interpretable gene signature for predicting the lymph node status of primary <scp>T1</scp> / <scp>T2</scp> oral cavity squamous cell carcinoma. International Journal of Cancer, 2022, 150, 450-460.	5.1	5
2	Precision health diagnostic and surveillance network uses <i>S</i> gene target failure (SGTF) combined with sequencing technologies to track emerging SARSâ€CoVâ€2 variants. Immunity, Inflammation and Disease, 2022, 10, .	2.7	4
3	Tyrosine Phosphorylation Profiling Revealed the Signaling Network Characteristics of CAMKK2 in Gastric Adenocarcinoma. Frontiers in Genetics, 2022, 13, .	2.3	4
4	Signaling alterations in oral keratinocytes in response to shisha and crude tobacco extract. Journal of Oral Pathology and Medicine, 2021, 50, 459-469.	2.7	2
5	Molecular alterations in oral cancer using high-throughput proteomic analysis of formalin-fixed paraffin-embedded tissue. Journal of Cell Communication and Signaling, 2021, 15, 447-459.	3.4	7
6	Proteomic and phosphoproteomic profiling of shammah induced signaling in oral keratinocytes. Scientific Reports, $2021,11,9397.$	3.3	2
7	Molecular Profiling Associated with Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2)-Mediated Carcinogenesis in Gastric Cancer. Journal of Proteome Research, 2021, 20, 2687-2703.	3.7	18
8	Proteomic Alterations Associated with Oral Cancer Patients with Tobacco Using Habits. OMICS A Journal of Integrative Biology, 2021, 25, 255-268.	2.0	4
9	Whole-Exome Sequencing Analysis of Oral Squamous Cell Carcinoma Delineated by Tobacco Usage Habits. Frontiers in Oncology, 2021, 11, 660696.	2.8	14
10	Molecular alterations in oral cancer between tobacco chewers and smokers using serum proteomics. Cancer Biomarkers, 2021, 31, 361-373.	1.7	6
11	Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma. Frontiers in Oncology, 2021, 11 , 677051 .	2.8	16
12	Hyperactivation of MEK/ERK pathway by Ca ²⁺ /calmodulinâ€dependent protein kinase kinase 2Apromotes cellular proliferation by activating cyclinâ€dependent kinasesÂand minichromosome maintenance proteinÂin gastric cancer cells. Molecular Carcinogenesis, 2021, 60, 769-783.	2.7	15
13	How to Achieve Therapeutic Response in Erlotinib-Resistant Head and Neck Squamous Cell Carcinoma? New Insights from Stable Isotope Labeling with Amino Acids in Cell Culture-Based Quantitative Tyrosine Phosphoproteomics. OMICS A Journal of Integrative Biology, 2021, 25, 605-616.	2.0	1
14	Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma. Cancer Letters, 2020, 471, 49-60.	7.2	12
15	Tissue and Cell-Free DNA-Based Epigenomic Approaches for Cancer Detection. Clinical Chemistry, 2020, 66, 105-116.	3.2	26
16	Multi-Omics Analysis to Characterize Cigarette Smoke Induced Molecular Alterations in Esophageal Cells. Frontiers in Oncology, 2020, 10, 1666.	2.8	1
17	Biomarkers for Lung Cancer Screening and Detection. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2411-2415.	2.5	32
18	Chromatin structure regulates cancer-specific alternative splicing events in primary HPV-related oropharyngeal squamous cell carcinoma. Epigenetics, 2020, 15, 959-971.	2.7	17

#	Article	IF	CITATIONS
19	<i>HIST1H2BB</i> and <i>MAGI2</i> Methylation and Somatic Mutations as Precision Medicine Biomarkers for Diagnosis and Prognosis of High-grade Serous Ovarian Cancer. Cancer Prevention Research, 2020, 13, 783-794.	1.5	11
20	Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma. Molecular Cancer Therapeutics, 2020, 19, 1797-1808.	4.1	9
21	Chronic shisha exposure alters phosphoproteome of oral keratinocytes. Journal of Cell Communication and Signaling, 2019, 13, 281-289.	3.4	4
22	Immune profiles in primary squamous cell carcinoma of the head and neck. Oral Oncology, 2019, 96, 77-88.	1.5	57
23	Chronic Exposure to Chewing Tobacco Induces Metabolic Reprogramming and Cancer Stem Cell-Like Properties in Esophageal Epithelial Cells. Cells, 2019, 8, 949.	4.1	21
24	Multiomic analysis of oral keratinocytes chronically exposed to shisha. Journal of Oral Pathology and Medicine, 2019, 48, 284-289.	2.7	9
25	PIM1 kinase promotes gallbladder cancer cell proliferation via inhibition of proline-rich Akt substrate of 40ÂkDa (PRAS40). Journal of Cell Communication and Signaling, 2019, 13, 163-177.	3.4	12
26	Secretome analysis of oral keratinocytes chronically exposed to shisha. Cancer Biomarkers, 2019, 25, 29-41.	1.7	5
27	Proteomic Changes in Oral Keratinocytes Chronically Exposed to Shisha (Water Pipe). OMICS A Journal of Integrative Biology, 2019, 23, 86-97.	2.0	8
28	<i>JAK3</i> Variant, Immune Signatures, DNA Methylation, and Social Determinants Linked to Survival Racial Disparities in Head and Neck Cancer Patients. Cancer Prevention Research, 2019, 12, 255-270.	1.5	19
29	MAP2K1 is a potential therapeutic target in erlotinib resistant head and neck squamous cell carcinoma. Scientific Reports, 2019, 9, 18793.	3.3	15
30	Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable $TGF\hat{l}^2$ enhance the efficacy of cancer immunotherapy. Nature Communications, 2018, 9, 741.	12.8	238
31	Role of protein kinase N2 (PKN2) in cigarette smoke-mediated oncogenic transformation of oral cells. Journal of Cell Communication and Signaling, 2018, 12, 709-721.	3.4	33
32	Molecular alterations associated with chronic exposure to cigarette smoke and chewing tobacco in normal oral keratinocytes. Cancer Biology and Therapy, 2018, 19, 773-785.	3.4	37
33	Cigarette smoke induces mitochondrial metabolic reprogramming in lung cells. Mitochondrion, 2018, 40, 58-70.	3.4	18
34	YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells. Cancer Research, 2018, 78, 168-181.	0.9	77
35	Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor. Oncoscience, 2018, 5, 21-38.	2.2	14
36	Testican 1 (SPOCK1) and protein tyrosine phosphatase, receptor type S (PTPRS) show significant increase in saliva of tobacco users with oral cancer. Translational Research in Oral Oncology, 2018, 3, 2057178X1880053.	3.3	1

#	Article	IF	Citations
37	Identification of potential biomarkers of head and neck squamous cell carcinoma using iTRAQ based quantitative proteomic approach. Data in Brief, 2018, 19, 1124-1130.	1.0	7
38	Functional characterization of alternatively spliced GSN in head and neck squamous cell carcinoma. Translational Research, 2018, 202, 109-119.	5.0	15
39	Growth of Malignant Non-CNS Tumors Alters Brain Metabolome. Frontiers in Genetics, 2018, 9, 41.	2.3	2
40	Growth of Triple Negative and Progesterone Positive Breast Cancer Causes Oxidative Stress and Down-Regulates Neuroprotective Transcription Factor NPAS4 and NPAS4-Regulated Genes in Hippocampal Tissues of TumorGraft Mice—an Aging Connection. Frontiers in Genetics, 2018, 9, 58.	2.3	8
41	miRNA and Proteomic Dysregulation in Non-Small Cell Lung Cancer in Response to Cigarette Smoke. MicroRNA (Shariqah, United Arab Emirates), 2018, 7, 38-53.	1.2	22
42	Cigarette smoke and chewing tobacco alter expression of different sets of miRNAs in oral keratinocytes. Scientific Reports, 2018, 8, 7040.	3.3	34
43	First Person: David Sidransky, MD. Cancer, 2018, 124, 3077-3078.	4.1	1
44	Role of the NOTCH Signaling Pathway in Head and Neck Cancer. Current Cancer Research, 2018, , 229-248.	0.2	4
45	Comparative mutational landscape analysis of patient-derived tumour xenografts. British Journal of Cancer, 2017, 116, 515-523.	6.4	11
46	Prenatal exposure to tobacco smoke leads to increased mitochondrial DNA content in umbilical cord serum associated to reduced gestational age. International Journal of Environmental Health Research, 2017, 27, 52-67.	2.7	9
47	Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. Human Cell, 2017, 30, 226-236.	2.7	7
48	Ranpirnase Eradicates Human Papillomavirus in Cultured Cells and Heals Anogenital Warts in a Phase I Study. Antiviral Therapy, 2017, 22, 247-255.	1.0	14
49	SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. Clinical Cancer Research, 2017, 23, 5162-5175.	7.0	64
50	Molecular Profiling of Malignant Pleural Effusion in Metastatic Non-Small Cell Lung Carcinoma: The Effect of Pre-analytical Factors. Annals of the American Thoracic Society, 2017, 14, 1169-1176.	3.2	45
51	In silico analysis of pathways activation landscape in oral squamous cell carcinoma and oral leukoplakia. Cell Death Discovery, 2017, 3, 17022.	4.7	27
52	Expression of GULP1 in bronchial epithelium is associated with the progression of emphysema in chronic obstructive pulmonary disease. Respiratory Medicine, 2017, 124, 72-78.	2.9	4
53	The <i>KRAS</i> -Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer. JAMA Oncology, 2017, 3, 483.	7.1	51
54	Prognostic biomarkers in patients with human immunodeficiency virusâ€positive disease with head and neck squamous cell carcinoma. Head and Neck, 2017, 39, 2433-2443.	2.0	5

#	Article	IF	CITATIONS
55	Integrated Analysis of Whole-Genome ChIP-Seq and RNA-Seq Data of Primary Head and Neck Tumor Samples Associates HPV Integration Sites with Open Chromatin Marks. Cancer Research, 2017, 77, 6538-6550.	0.9	50
56	Advancing toward a molecular characterization of polymorphous low grade adenocarcinoma. Oral Oncology, 2017, 74, 192-193.	1.5	9
57	Chronic Cigarette Smoke Mediated Global Changes in Lung Mucoepidermoid Cells: A Phosphoproteomic Analysis. OMICS A Journal of Integrative Biology, 2017, 21, 474-487.	2.0	38
58	A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non–Small Cell Lung Cancer and Serum DNA. Clinical Cancer Research, 2017, 23, 7141-7152.	7.0	116
59	NSD1- and NSD2-damaging mutations define a subset of laryngeal tumors with favorable prognosis. Nature Communications, 2017, 8, 1772.	12.8	40
60	INSIG2 rs7566605 single nucleotide variant and global DNA methylation index levels are associated with weight loss in a personalized weight reduction program. Molecular Medicine Reports, 2017, 17, 1699-1709.	2.4	3
61	Long-Term Cigarette Smoke Exposure and Changes in MiRNA Expression and Proteome in Non-Small-Cell Lung Cancer. OMICS A Journal of Integrative Biology, 2017, 21, 390-403.	2.0	24
62	Investigation of curcumin-mediated signalling pathways in head and neck squamous cell carcinoma. Translational Research in Oral Oncology, 2017, 2, 2057178X1774314.	3.3	0
63	High-resolution microbiome profiling uncovers <i>Fusobacterium nucleatum</i> , <i>Lactobacillus gasseri/johnsonii</i> , and <i>Lactobacillus vaginalis</i> associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiation. Oncotarget, 2017, 8, 110931-110948.	1.8	79
64	Chemo brain or tumor brain - that is the question: the presence of extracranial tumors profoundly affects molecular processes in the prefrontal cortex of TumorGraft mice. Aging, 2017, 9, 1660-1676.	3.1	9
65	Promoter methylation of MCAM, ERl^\pm and ERl^2 in serum of early stage prostate cancer patients. Oncotarget, 2017, 8, 15431-15440.	1.8	31
66	Early detection of gastric cancer using global, genome-wide and <i>IRF4, ELMO1, CLIP4</i> and <i>MSC</i> DNA methylation in endoscopic biopsies. Oncotarget, 2017, 8, 38501-38516.	1.8	36
67	Growth of malignant extracranial tumors alters microRNAome in the prefrontal cortex of TumorGraft mice. Oncotarget, 2017, 8, 88276-88293.	1.8	10
68	16S rRNA amplicon sequencing identifies microbiota associated with oral cancer, human papilloma virus infection and surgical treatment. Oncotarget, 2016, 7, 51320-51334.	1.8	237
69	Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer. PLoS ONE, 2016, 11, e0144862.	2.5	27
70	Adenoid cystic carcinoma: emerging role of translocations and gene fusions. Oncotarget, 2016, 7, 66239-66254.	1.8	54
71	Pro-fibrotic pathway activation in trabecular meshwork and lamina cribrosa is the main driving force of glaucoma. Cell Cycle, 2016, 15, 1643-1652.	2.6	43
72	High-performance detection of somatic D-loop mutation in urothelial cell carcinoma patients by polymorphism ratio sequencing. Journal of Molecular Medicine, 2016, 94, 1015-1024.	3.9	7

#	Article	IF	CITATIONS
73	Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes. Cancer Prevention Research, 2016, 9, 915-924.	1.5	29
74	In silico Pathway Activation Network Decomposition Analysis (iPANDA) as a method for biomarker development. Nature Communications, 2016, 7, 13427.	12.8	126
75	A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma. Scientific Reports, 2016, 6, 36132.	3.3	36
76	Common pathway signature in lung and liver fibrosis. Cell Cycle, 2016, 15, 1667-1673.	2.6	43
77	Antiviral effect of ranpirnase against Ebola virus. Antiviral Research, 2016, 132, 210-218.	4.1	16
78	Dysregulation of splicing proteins in head and neck squamous cell carcinoma. Cancer Biology and Therapy, 2016, 17, 219-229.	3.4	25
79	Chronic exposure to cigarette smoke leads to activation of p21 (RAC1)-activated kinase 6 (PAK6) in non-small cell lung cancer cells. Oncotarget, 2016, 7, 61229-61245.	1.8	45
80	Macrophage migration inhibitory factor - a therapeutic target in gallbladder cancer. BMC Cancer, 2015, 15, 843.	2.6	33
81	An integrated genome-wide approach to discover deregulated microRNAs in non-small cell lung cancer: Clinical significance of miR-23b-3p deregulation. Scientific Reports, 2015, 5, 13236.	3.3	32
82	Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients. Human Genome Variation, 2015, 2, 15009.	0.7	58
83	Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features. Cancer Prevention Research, 2015, 8, 287-295.	1.5	43
84	Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use. Cancer Prevention Research, 2015, 8, 208-221.	1.5	51
85	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Science Translational Medicine, 2015, 7, 293ra104.	12.4	372
86	A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 376-382.	1.5	50
87	Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Seminars in Cancer Biology, 2015, 35, S5-S24.	9.6	231
88	Notch1 Mutations Are Drivers of Oral Tumorigenesis. Cancer Prevention Research, 2015, 8, 277-286.	1.5	78
89	Understanding the MIG6–EGFR Signaling Axis in Lung Tumorigenesis. Cancer Discovery, 2015, 5, 472-474.	9.4	8
90	<i>PARD3</i> Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. Cancer Research, 2015, 75, 1287-1297.	0.9	44

#	Article	IF	Citations
91	Global and gene-specific DNA methylation pattern discriminates cholecystitis from gallbladder cancer patients in Chile. Future Oncology, 2015, 11, 233-249.	2.4	23
92	Elevated AKAP12 in Paclitaxel-Resistant Serous Ovarian Cancer Cells Is Prognostic and Predictive of Poor Survival in Patients. Journal of Proteome Research, 2015, 14, 1900-1910.	3.7	41
93	Chronic exposure to chewing tobacco selects for overexpression of stearoyl-CoA desaturase in normal oral keratinocytes. Cancer Biology and Therapy, 2015, 16, 1593-1603.	3.4	31
94	<i>Paired Box 5</i> Methylation Detection by Droplet Digital PCR for Ultra-Sensitive Deep Surgical Margins Analysis of Head and Neck Squamous Cell Carcinoma. Cancer Prevention Research, 2015, 8, 1017-1026.	1.5	21
95	MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. Journal of Clinical Neuroscience, 2015, 22, 1938-1942.	1.5	21
96	Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA. Nature Communications, 2015, 6, 8258.	12.8	129
97	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	9.6	220
98	Silencing of highâ€mobility group box 2 (HMGB2) modulates cisplatin and 5â€fluorouracil sensitivity in head and neck squamous cell carcinoma. Proteomics, 2015, 15, 383-393.	2.2	30
99	Epigenetic silencing of S100A2 in bladder and head and neck cancers. Oncoscience, 2015, 2, 410-418.	2.2	8
100	Key tumor suppressor genes inactivated by "greater promoter―methylation and somatic mutations in head and neck cancer. Epigenetics, 2014, 9, 1031-1046.	2.7	122
101	Activation of the <i>NOTCH</i> Pathway in Head and Neck Cancer. Cancer Research, 2014, 74, 1091-1104.	0.9	181
102	Detection of Methylated CDO1 in Plasma of Colorectal Cancer; A PCR Study. PLoS ONE, 2014, 9, e113546.	2.5	26
103	Cold atmospheric plasma treatment selectively targets head and neck squamous cell carcinoma cells. International Journal of Molecular Medicine, 2014, 34, 941-946.	4.0	164
104	Genome-Wide and Gene-Specific Epigenomic Platforms for Hepatocellular Carcinoma Biomarker Development Trials. Gastroenterology Research and Practice, 2014, 2014, 1-9.	1.5	12
105	KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells. Molecular Cancer Therapeutics, 2014, 13, 1611-1624.	4.1	51
106	Clusterin Is a Gene-Specific Target of microRNA-21 in Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2014, 20, 868-877.	7.0	26
107	Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population. Epigenetics, 2014, 9, 308-317.	2.7	28
108	The TGFβ–miR200–MIG6 Pathway Orchestrates the EMT-Associated Kinase Switch That Induces Resistance to EGFR Inhibitors. Cancer Research, 2014, 74, 3995-4005.	0.9	123

#	Article	IF	CITATIONS
109	Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. Clinical Cancer Research, 2014, 20, 2476-2484.	7.0	140
110	GSTP1Promoter Methylation is Associated with Recurrence in Early Stage Prostate Cancer. Journal of Urology, 2014, 192, 1542-1548.	0.4	48
111	Patientâ€derived xenografts for individualized care in advanced sarcoma. Cancer, 2014, 120, 2006-2015.	4.1	154
112	Differential promoter methylation of kinesin family member 1a in plasma is associated with breast cancer and DNA repair capacity. Oncology Reports, 2014, 32, 505-512.	2.6	43
113	Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer. Oncology Reports, 2014, 31, 1014-1020.	2.6	22
114	MDA-9/Syntenin regulates differentiation and angiogenesis programs in head and neck squamous cell carcinoma. Oncoscience, 2014, 1, 725-737.	2.2	24
115	Epigenetic inactivation of <i>VGF</i> associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine. Oncotarget, 2014, 5, 3350-3361.	1.8	17
116	An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine. Oncotarget, 2014, 5, 5218-5233.	1.8	19
117	Abstract B25: KRAS mutation status is associated with enhanced dependency on purine biosynthesis and related pathways in non small cell lung cancer cells. , 2014, , .		0
118	SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling. Journal of Molecular Medicine, 2013, 91, 381-393.	3.9	28
119	Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer. JAMA - Journal of the American Medical Association, 2013, 309, 1493.	7.4	775
120	Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2308-2316.	2.3	52
121	Hypermethylation of Genes Detected in Urine from Ghanaian Adults with Bladder Pathology Associated with Schistosoma haematobium Infection. PLoS ONE, 2013, 8, e59089.	2.5	33
122	Clinical Correlates of Promoter Hypermethylation of Four Target Genes in Head and Neck Cancer: A Cooperative Group Correlative Study. Clinical Cancer Research, 2013, 19, 2528-2540.	7.0	27
123	PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival. Cancer Immunology Research, 2013, 1, 54-63.	3.4	333
124	Genome-wide methylation profiling and the PI3K-AKT pathway analysis associated with smoking in urothelial cell carcinoma. Cell Cycle, 2013, 12, 1058-1070.	2.6	36
125	Cigarette smoke induces methylation of the tumor suppressor gene <i><i>NISCH</i>Epigenetics, 2013, 8, 383-388.</i>	2.7	28
126	Identification of guanine nucleotide-binding protein \hat{I}^3 -7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling. International Journal of Oncology, 2013, 42, 1427-1436.	3.3	31

#	Article	IF	CITATIONS
127	The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors. PLoS ONE, 2013, 8, e68966.	2.5	31
128	Association of Promoter Methylation of VGF and PGP9.5 with Ovarian Cancer Progression. PLoS ONE, 2013, 8, e70878.	2.5	34
129	Integrated genomics and avatar mouse models for personalized cancer treatment Journal of Clinical Oncology, 2013, 31, 2511-2511.	1.6	0
130	Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft. Journal of Clinical Oncology, 2012, 30, e45-e48.	1.6	79
131	Correlation between BRAF mutation and promoter methylation of TIMP3, RARÎ ² 2 and RASSF1A in thyroid cancer. Epigenetics, 2012, 7, 710-719.	2.7	51
132	Methylation of death-associated protein kinase is associated with cetuximab and erlotinib resistance. Cell Cycle, 2012, 11, 1656-1663.	2.6	55
133	Inhibition of TGF-β Enhances the <i>In Vivo</i> Antitumor Efficacy of EGF Receptor–Targeted Therapy. Molecular Cancer Therapeutics, 2012, 11, 2429-2439.	4.1	66
134	Clinical and public health research using methylated DNA Immunoprecipitation (MeDIP): A comparison of commercially available kits to examine differential DNA methylation across the genome. Epigenetics, 2012, 7, 106-112.	2.7	9
135	Epigenetic Silencing of HOPX Promotes Cancer Progression in Colorectal Cancer. Neoplasia, 2012, 14, 559-IN6.	5.3	55
136	Cysteine Dioxygenase 1 Is a Tumor Suppressor Gene Silenced by Promoter Methylation in Multiple Human Cancers. PLoS ONE, 2012, 7, e44951.	2. 5	110
137	A <i>IM1</i> promoter hypermethylation as a predictor of decreased risk of recurrence following radical prostatectomy. Prostate, 2012, 72, 1133-1139.	2.3	18
138	Tissue imprint for molecular mapping of deep surgical margins in patients with head and neck squamous cell carcinoma. Head and Neck, 2012, 34, 1529-1536.	2.0	19
139	Detection of mitochondrial deoxyribonucleic acid alterations in urine from urothelial cell carcinoma patients. International Journal of Cancer, 2012, 131, 158-164.	5.1	23
140	Mitochondrial DNA mutations in respiratory complex†in neverâ€smoker lung cancer patients contribute to lung cancer progression and associated with <i>EGFR</i> gene mutation. Journal of Cellular Physiology, 2012, 227, 2451-2460.	4.1	74
141	Dose-Dependent Activation of Putative Oncogene SBSN by BORIS. PLoS ONE, 2012, 7, e40389.	2.5	33
142	Suprabasin Is Hypomethylated and Associated with Metastasis in Salivary Adenoid Cystic Carcinoma. PLoS ONE, 2012, 7, e48582.	2.5	34
143	OGDHL Is a Modifier of AKT-Dependent Signaling and NF-κB Function. PLoS ONE, 2012, 7, e48770.	2.5	56
144	Detection of Promoter Hypermethylation in Salivary Rinses as a Biomarker for Head and Neck Squamous Cell Carcinoma Surveillance. Clinical Cancer Research, 2011, 17, 4782-4789.	7.0	84

#	Article	IF	CITATIONS
145	Cancer epigenetics: above and beyond. Toxicology Mechanisms and Methods, 2011, 21, 275-288.	2.7	82
146	An Epigenetic Marker Panel for Detection of Lung Cancer Using Cell-Free Serum DNA. Clinical Cancer Research, 2011, 17, 4494-4503.	7.0	126
147	Adenylate Kinase 3 Sensitizes Cells to Cigarette Smoke Condensate Vapor Induced Cisplatin Resistance. PLoS ONE, 2011, 6, e20806.	2.5	61
148	Promoter methylation of leukemia inhibitory factor receptor gene in colorectal carcinoma. International Journal of Oncology, 2011, 39, 337-44.	3.3	16
149	Promoter methylation of heat shock protein B2 in human esophageal squamous cell carcinoma. International Journal of Oncology, 2011, 38, 1129-35.	3.3	8
150	p53-Reactivating small molecules induce apoptosis and enhance chemotherapeutic cytotoxicity in head and neck squamous cell carcinoma. Oral Oncology, 2011, 47, 8-15.	1.5	86
151	Evaluation of MYB promoter methylation in salivary adenoid cystic carcinoma. Oral Oncology, 2011, 47, 251-255.	1.5	17
152	Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i> . Science, 2011, 333, 1154-1157.	12.6	1,568
153	A survey of methylated candidate tumor suppressor genes in nasopharyngeal carcinoma. International Journal of Cancer, 2011, 128, 1393-1403.	5.1	59
154	Cigarette smoke induces promoter methylation of singleâ€stranded DNAâ€binding protein 2 in human esophageal squamous cell carcinoma. International Journal of Cancer, 2011, 128, 2261-2273.	5.1	39
155	Mitochondrial Subversion in Cancer. Cancer Prevention Research, 2011, 4, 638-654.	1.5	160
156	î"Np63α Confers Tumor Cell Resistance to Cisplatin through the AKT1 Transcriptional Regulation. Cancer Research, 2011, 71, 1167-1176.	0.9	51
157	An EGFR-ERK-SOX9 Signaling Cascade Links Urothelial Development and Regeneration to Cancer. Cancer Research, 2011, 71, 3812-3821.	0.9	101
158	BORIS Binding to the Promoters of Cancer Testis Antigens, <i>MAGEA2</i> , <i>MAGEA3</i> , and <i>MAGEA4</i> , Is Associated with Their Transcriptional Activation in Lung Cancer. Clinical Cancer Research, 2011, 17, 4267-4276.	7.0	44
159	Assembly and Initial Characterization of a Panel of 85 Genomically Validated Cell Lines from Diverse Head and Neck Tumor Sites. Clinical Cancer Research, 2011, 17, 7248-7264.	7.0	230
160	Tumor Protein p63/Nuclear Factor κB Feedback Loop in Regulation of Cell Death. Journal of Biological Chemistry, 2011, 286, 43204-43213.	3.4	14
161	Characterization of the Methylation Patterns in Human Papillomavirus Type 16 Viral DNA in Head and Neck Cancers. Cancer Prevention Research, 2011, 4, 207-217.	1.5	41
162	Integrated, Genome-Wide Screening for Hypomethylated Oncogenes in Salivary Gland Adenoid Cystic Carcinoma. Clinical Cancer Research, 2011, 17, 4320-4330.	7.0	68

#	Article	IF	CITATIONS
163	A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. Molecular Cancer Therapeutics, 2011, 10, 1311-1316.	4.1	354
164	Genetic and Epigenetic Analysis of erbB Signaling Pathway Genes in Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1887-1893.	1.1	31
165	DNA methylation markers in colorectal cancer. Cancer and Metastasis Reviews, 2010, 29, 181-206.	5.9	259
166	Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer, 2010, 116, 5517-5526.	4.1	66
167	Quantitative detection of Merkel cell virus in human tissues and possible mode of transmission. International Journal of Cancer, 2010, 126, 2991-2996.	5.1	146
168	Cellular transformation by cigarette smoke extract involves alteration of glycolysis and mitochondrial function in esophageal epithelial cells. International Journal of Cancer, 2010, 127, 269-281.	5.1	39
169	KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses. International Journal of Cancer, 2010, 127, 2351-2359.	5.1	75
170	Neurofilament Heavy Polypeptide Regulates the Akt- \hat{l}^2 -Catenin Pathway in Human Esophageal Squamous Cell Carcinoma. PLoS ONE, 2010, 5, e9003.	2. 5	40
171	Quantitative Methylation Profiles for Multiple Tumor Suppressor Gene Promoters in Salivary Gland Tumors. PLoS ONE, 2010, 5, e10828.	2.5	27
172	Regulation of p53 Family Member Isoform ΔNp63α by the Nuclear Factor-κB Targeting Kinase IκB Kinase β. Cancer Research, 2010, 70, 1419-1429.	0.9	41
173	The Ras Effector RASSF2 Controls the PAR-4 Tumor Suppressor. Molecular and Cellular Biology, 2010, 30, 2608-2620.	2.3	38
174	<i>Endothelin Receptor Type B</i> Gene Promoter Hypermethylation in Salivary Rinses Is Independently Associated with Risk of Oral Cavity Cancer and Premalignancy. Cancer Prevention Research, 2010, 3, 1093-1103.	1.5	67
175	Identification of Hypermethylated Genes Associated with Cisplatin Resistance in Human Cancers. Cancer Research, 2010, 70, 2870-2879.	0.9	107
176	Mitochondrial DNA Mutation in Normal Margins and Tumors of Recurrent Head and Neck Squamous Cell Carcinoma Patients. Cancer Prevention Research, 2010, 3, 1205-1211.	1.5	56
177	Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR. Clinical Cancer Research, 2010, 16, 3463-3472.	7.0	105
178	p53 Regulates the Ras Circuit to Inhibit the Expression of a Cancer-Related Gene Signature by Various Molecular Pathways. Cancer Research, 2010, 70, 2274-2284.	0.9	66
179	Phospho-ΔNp63α/NF-Y protein complex transcriptionally regulates DDIT3 expression in squamous cell carcinoma cells upon cisplatin exposure. Cell Cycle, 2010, 9, 328-338.	2.6	28
180	Regulation of ΔNp63α by NFκΒÂ. Cell Cycle, 2010, 9, 4841-4847.	2.6	21

#	Article	IF	CITATIONS
181	Global DNA hypomethylation is associated with in utero exposure to cotinine and perfluorinated alkyl compounds. Epigenetics, 2010, 5, 539-546.	2.7	172
182	Yes-associated protein 1 regulates the stability of î"Np63α. Cell Cycle, 2010, 9, 162-167.	2.6	17
183	Changes in CpG Islands Promoter Methylation Patterns during Ductal Breast Carcinoma Progression. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2694-2700.	2.5	73
184	Association between Lifestyle Factors and CpG Island Methylation in a Cancer-Free Population. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2984-2991.	2.5	68
185	Pharmacologic Unmasking of Epigenetically Silenced Genes in Breast Cancer. Clinical Cancer Research, 2009, 15, 1184-1191.	7.0	64
186	The Ligamp TP53 Assay for Detection of Minimal Residual Disease in Head and Neck Squamous Cell Carcinoma Surgical Margins. Clinical Cancer Research, 2009, 15, 7658-7665.	7.0	34
187	Molecular techniques and genetic alterations in head and neck cancer. Oral Oncology, 2009, 45, 335-339.	1.5	67
188	Forced cytochrome B gene mutation expression induces mitochondrial proliferation and prevents apoptosis in human uroepithelial SVâ€HUCâ€1 cells. International Journal of Cancer, 2009, 125, 2829-2835.	5.1	35
189	Following Mitochondrial Footprints through a Long Mucosal Path to Lung Cancer. PLoS ONE, 2009, 4, e6533.	2.5	30
190	Promoter DNA Methylation of Oncostatin M receptor- \hat{l}^2 as a Novel Diagnostic and Therapeutic Marker in Colon Cancer. PLoS ONE, 2009, 4, e6555.	2.5	81
191	Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. Breast Cancer Research and Treatment, 2008, 109, 27-34.	2.5	47
192	Multiple strand displacement amplification of mitochondrial DNA from clinical samples. BMC Medical Genetics, 2008, 9, 7.	2.1	14
193	Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. Prostate, 2008, 68, 418-426.	2.3	38
194	The role of PGP9.5 as a tumor suppressor gene in human cancer. International Journal of Cancer, 2008, 123, 753-759.	5.1	55
195	DCC promoter hypermethylation in esophageal squamous cell carcinoma. International Journal of Cancer, 2008, 122, 2498-2502.	5.1	40
196	MicroRNA alterations in head and neck squamous cell carcinoma. International Journal of Cancer, 2008, 123, 2791-2797.	5.1	239
197	Profiling the expression pattern of GPI transamidase complex subunits in human cancer. Modern Pathology, 2008, 21, 979-991.	5.5	47
198	Performance of mitochondrial DNA mutations detecting early stage cancer. BMC Cancer, 2008, 8, 285.	2.6	57

#	Article	IF	Citations
199	Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research, 2008, 14, 97-107.	7.0	163
200	Overexpression of AQP5, a putative oncogene, promotes cell growth and transformation. Cancer Letters, 2008, 264, 54-62.	7.2	82
201	Epigenetic silencing of human T (brachyury homologue) gene in non-small-cell lung cancer. Biochemical and Biophysical Research Communications, 2008, 365, 221-226.	2.1	31
202	Membrane trafficking of AQP5 and cAMP dependent phosphorylation in bronchial epithelium. Biochemical and Biophysical Research Communications, 2008, 366, 321-327.	2.1	53
203	The effect of aquaporin 5 overexpression on the Ras signaling pathway. Biochemical and Biophysical Research Communications, 2008, 367, 291-298.	2.1	72
204	Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancer. Biochemical and Biophysical Research Communications, 2008, 370, 38-43.	2.1	115
205	Role of Human Aquaporin 5 In Colorectal Carcinogenesis. American Journal of Pathology, 2008, 173, 518-525.	3.8	133
206	Tissue Inhibitor of Metalloproteinases-3 Promoter Methylation is an Independent Prognostic Factor for Bladder Cancer. Journal of Urology, 2008, 179, 743-747.	0.4	48
207	ATM kinase is a master switch for the Δ Np63α phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle, 2008, 7, 2846-2855.	2.6	48
208	U-box-type ubiquitin E4 ligase, UFD2a attenuates cisplatin mediated degradation of & amp;Delta;Np63& amp;alpha;. Cell Cycle, 2008, 7, 1231-1237.	2.6	37
209	Midkine induces epithelial-mesenchymal transition through Notch2/Jak2-Stat3 signaling in human keratinocytes. Cell Cycle, 2008, 7, 1613-1622.	2.6	65
210	Mitochondrial Cytochrome B Gene Mutation Promotes Tumor Growth in Bladder Cancer. Cancer Research, 2008, 68, 700-706.	0.9	117
211	The Oral Cavity as a Molecular Mirror of Lung Carcinogenesis. Cancer Prevention Research, 2008, 1, 12-14.	1.5	26
212	Aberrant Promoter Methylation of Multiple Genes during Pathogenesis of Bladder Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2786-2794.	2.5	72
213	ssDNA-Binding Protein 2 Is Frequently Hypermethylated and Suppresses Cell Growth in Human Prostate Cancer. Clinical Cancer Research, 2008, 14, 3754-3760.	7.0	32
214	HOP/OB1/NECC1 Promoter DNA Is Frequently Hypermethylated and Involved in Tumorigenic Ability in Esophageal Squamous Cell Carcinoma. Molecular Cancer Research, 2008, 6, 31-41.	3.4	44
215	Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome. Cancer Research, 2008, 68, 2661-2670.	0.9	131
216	Efficacy of Weekly Docetaxel and Bevacizumab in Mesenchymal Chondrosarcoma: A New Theranostic Method Combining Xenografted Biopsies with a Mathematical Model. Cancer Research, 2008, 68, 9033-9040.	0.9	61

#	Article	IF	Citations
217	Inverse Relationship between Human Papillomavirus-16 Infection and Disruptive <i>p53 </i> Gene Mutations in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research, 2008, 14, 366-369.	7.0	213
218	Expression of Aquaporin 5 (AQP5) Promotes Tumor Invasion in Human Non Small Cell Lung Cancer. PLoS ONE, 2008, 3, e2162.	2.5	124
219	OPCML Is a Broad Tumor Suppressor for Multiple Carcinomas and Lymphomas with Frequently Epigenetic Inactivation. PLoS ONE, 2008, 3, e2990.	2.5	92
220	Human AQP5 Plays a Role in the Progression of Chronic Myelogenous Leukemia (CML). PLoS ONE, 2008, 3, e2594.	2.5	69
221	Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7540-7545.	7.1	175
222	A Promoter Methylation Pattern in the <i>N</i> -Methyl- <scp>d</scp> -Aspartate Receptor 2B Gene Predicts Poor Prognosis in Esophageal Squamous Cell Carcinoma. Clinical Cancer Research, 2007, 13, 6658-6665.	7.0	20
223	p63 Transcriptional Regulation of Epithelial Integrity and Cancer. Cell Cycle, 2007, 6, 240-245.	2.6	30
224	Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4712-4718.	3.6	95
225	LOXL1 and LOXL4 Are Epigenetically Silenced and Can Inhibit Ras/Extracellular Signal-Regulated Kinase Signaling Pathway in Human Bladder Cancer. Cancer Research, 2007, 67, 4123-4129.	0.9	102
226	High Promoter Methylation Levels of <i>APC</i> Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients. Clinical Cancer Research, 2007, 13, 6122-6129.	7.0	122
227	Alteration of Cellular and Humoral Immunity by Mutant p53 Protein and Processed Mutant Peptide in Head and Neck Cancer. Clinical Cancer Research, 2007, 13, 7199-7206.	7.0	27
228	A p53-type response element in the GDF15 promoter confers high specificity for p53 activation. Biochemical and Biophysical Research Communications, 2007, 354, 913-918.	2.1	67
229	TAp63γ regulates hOGG1 and repair of oxidative damage in cancer cell lines. Biochemical and Biophysical Research Communications, 2007, 356, 823-828.	2.1	4
230	<i>TP53</i> Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 2007, 357, 2552-2561.	27.0	680
231	Alterations of GPI transamidase subunits in head and neck squamous carcinoma. Molecular Cancer, 2007, 6, 74.	19.2	19
232	Quantitative hypermethylation of NMDAR2B in human gastric cancer. International Journal of Cancer, 2007, 121, 1994-2000.	5.1	60
233	Positive Correlation of Tissue Inhibitor of Metalloproteinase-3 and Death-Associated Protein Kinase Hypermethylation in Head and Neck Squamous Cell Carcinoma. Laryngoscope, 2007, 117, 1376-1380.	2.0	18
234	Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecologic Oncology, 2007, 105, 662-666.	1.4	60

#	Article	IF	Citations
235	Aquaporin 1 Is Overexpressed in Lung Cancer and Stimulates NIH-3T3 Cell Proliferation and Anchorage-Independent Growth. American Journal of Pathology, 2006, 168, 1345-1353.	3.8	150
236	An Oligonucleotide Microarray for High-Throughput Sequencing of the Mitochondrial Genome. Journal of Molecular Diagnostics, 2006, 8, 476-482.	2.8	65
237	Mitochondrial DNA mutations in preneoplastic lesions of the gastrointestinal tract: A biomarker for the early detection of cancer. Molecular Cancer, 2006, 5, 73.	19.2	55
238	Detection of Aberrant Methylation of Four Genes in Plasma DNA for the Detection of Breast Cancer. Journal of Clinical Oncology, 2006, 24, 4262-4269.	1.6	219
239	A novel response element confers p63- and p73-specific activation of the WNT4 promoter. Biochemical and Biophysical Research Communications, 2006, 339, 1120-1128.	2.1	35
240	Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. Journal of Molecular Medicine, 2006, 84, 911-918.	3.9	54
241	P63 and P73: Teammates or adversaries?. Cancer Cell, 2006, 9, 1-2.	16.8	15
242	Head and neck cancer cell lines exhibit differential mitochondrial repair deficiency in response to 4NQO. Oral Oncology, 2006, 42, 201-207.	1.5	27
243	Targeting of mutant hogg1in mammalian mitochondria and nucleus: effect on cellular survival upon oxidative stress. BMC Cancer, 2006, 6, 235.	2.6	53
244	RASSF1A hypermethylation and its inverse correlation with BRAF and/or KRAS mutations in MSI-associated endometrial carcinoma. International Journal of Cancer, 2006, 119, 1316-1321.	5.1	35
245	Assessment of gene promoter hypermethylation for detection of cervical neoplasia. International Journal of Cancer, 2006, 119, 1908-1914.	5.1	97
246	Increased plasma DNA integrity index in head and neck cancer patients. International Journal of Cancer, 2006, 119, 2673-2676.	5.1	86
247	î"Np63α Overexpression Induces Downregulation of Sirt1 and an Accelerated Aging Phenotype in the Mouse. Cell Cycle, 2006, 5, 2005-2011.	2.6	85
248	Deleted in Colorectal Cancer Is a Putative Conditional Tumor-Suppressor Gene Inactivated by Promoter Hypermethylation in Head and Neck Squamous Cell Carcinoma. Cancer Research, 2006, 66, 9401-9407.	0.9	63
249	Overexpression of Glycosylphosphatidylinositol (GPI) Transamidase Subunits Phosphatidylinositol Glycan Class T and/or GPI Anchor Attachment 1 Induces Tumorigenesis and Contributes to Invasion in Human Breast Cancer. Cancer Research, 2006, 66, 9829-9836.	0.9	62
250	Detection of Serum Deoxyribonucleic Acid Methylation Markers: A Novel Diagnostic Tool for Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 98-104.	3.6	59
251	Fluorescence Visualization in Oral Neoplasia: Shedding Light on an Old Problem: Fig. 1 Clinical Cancer Research, 2006, 12, 6594-6597.	7.0	25
252	Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis. Molecular Cancer Research, 2006, 4, 1-8.	3.4	85

#	Article	lF	CITATIONS
253	Mitochondrial DNA Content Increase in Response to Cigarette Smoking. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 19-24.	2.5	87
254	PGP9.5 Methylation in Diffuse-Type Gastric Cancer. Cancer Research, 2006, 66, 3921-3927.	0.9	64
255	LKB1/STK11 Suppresses Cyclooxygenase-2 Induction and Cellular Invasion through PEA3 in Lung Cancer. Cancer Research, 2006, 66, 7870-7879.	0.9	43
256	Decreased Mitochondrial DNA Content in Posttreatment Salivary Rinses from Head and Neck Cancer Patients. Clinical Cancer Research, 2006, 12, 1564-1569.	7.0	51
257	N-Methyl-d-Aspartate Receptor Type 2B Is Epigenetically Inactivated and Exhibits Tumor-Suppressive Activity in Human Esophageal Cancer. Cancer Research, 2006, 66, 3409-3418.	0.9	97
258	Quantitation of Promoter Methylation of Multiple Genes in Urine DNA and Bladder Cancer Detection. Journal of the National Cancer Institute, 2006, 98, 996-1004.	6.3	237
259	The effect of p53â€RNAi and p53 knockout on human 8â€oxoguanine DNA glycosylase (hOgg1) activity. FASEB Journal, 2006, 20, 112-114.	0.5	44
260	Oxidized guanine lesions and hOgg1 activity in lung cancer. Oncogene, 2005, 24, 4496-4508.	5.9	76
261	Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Modern Pathology, 2005, 18, 898-902.	5.5	64
262	p63-Specific Activation of the BPAC-1e Promoter. Journal of Investigative Dermatology, 2005, 125, 52-60.	0.7	35
263	Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer. International Journal of Cancer, 2005, 113, 1022-1025.	5.1	41
264	Tumor-specific changes in mtDNA content in human cancer. International Journal of Cancer, 2005, 116, 920-924.	5.1	160
265	Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. International Journal of Cancer, 2005, 117, 605-610.	5.1	106
266	Absence of V599E <i>BRAF</i> mutations in desmoplastic melanomas. Cancer, 2005, 103, 788-792.	4.1	60
267	T1799ABRAFMutations in Conjunctival Melanocytic Lesions. , 2005, 46, 3027.		75
268	Colorimetric approach to high-throughput mutation analysis. BioTechniques, 2005, 38, 635-639.	1.8	8
269	Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in Urine Sediment Distinguish Prostate Cancer Patients From Control Subjects. Journal of Clinical Oncology, 2005, 23, 6569-6575.	1.6	227
270	PGP9.5 Promoter Methylation Is an Independent Prognostic Factor for Esophageal Squamous Cell Carcinoma. Cancer Research, 2005, 65, 4963-4968.	0.9	110

#	Article	IF	Citations
271	Increased Mitochondrial DNA Content in Saliva Associated with Head and Neck Cancer. Clinical Cancer Research, 2005, 11, 2486-2491.	7.0	148
272	Promoter Hypermethylation as an Independent Prognostic Factor for Relapse in Patients with Prostate Cancer Following Radical Prostatectomy. Clinical Cancer Research, 2005, 11, 8321-8325.	7.0	129
273	ΔNp63α Levels Correlate with Clinical Tumor Response to Cisplatin. Cell Cycle, 2005, 4, 1313-1315.	2.6	94
274	Frequent 14-3-3 Ïf Promoter Methylation in Benign and Malignant Prostate Lesions. DNA and Cell Biology, 2005, 24, 264-269.	1.9	60
275	Differential Recognition of Response Elements Determines Target Gene Specificity forp53 and p63. Molecular and Cellular Biology, 2005, 25, 6077-6089.	2.3	136
276	Ribonucleases as a Novel Pro-Apoptotic Anticancer Strategy: Review of the Preclinical and Clinical Data for Ranpirnase. Cancer Investigation, 2005, 23, 643-650.	1.3	101
277	MT1G Hypermethylation Is Associated with Higher Tumor Stage in Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1274-1278.	2.5	65
278	Uncommon Mutation, but Common Amplifications, of the PIK3 CAGene in Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 4688-4693.	3.6	189
279	Mitochondrial DNA as a Cancer Biomarker. Journal of Molecular Diagnostics, 2005, 7, 258-267.	2.8	77
280	BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6373-6379.	3.6	893
281	Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Research, 2005, 7, R609-16.	5.0	207
282	DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Research, 2005, 65, 758-66.	0.9	91
283	RACK1 and Stratifin Target & Delta; Np63& Delta; Np63& Delta; for a Proteasome Degradation in Head and Neck Squamous Cell Carcinoma Cells upon DNA Damage. Cell Cycle, 2004, 3, 1285-1295.	2.6	97
284	Exon 15 <i>BRAF</i> Mutations Are Uncommon in Melanomas Arising in Nonsun-Exposed Sites. Clinical Cancer Research, 2004, 10, 3444-3447.	7.0	128
285	Inverse Correlation between Cyclin A1 Hypermethylation and p53 Mutation in Head and Neck Cancer Identified by Reversal of Epigenetic Silencing. Cancer Research, 2004, 64, 5982-5987.	0.9	127
286	The Human MitoChip: A High-Throughput Sequencing Microarray for Mitochondrial Mutation Detection. Genome Research, 2004, 14, 812-819.	5 . 5	218
287	Quantitative < b > <i>RARβ2 < /i> < /b> Hypermethylation. Clinical Cancer Research, 2004, 10, 4010-4014.</i>	7.0	117
288	Mutational Analysis of <i>BRAF</i> in Fine Needle Aspiration Biopsies of the Thyroid: A Potential Application for the Preoperative Assessment of Thyroid Nodules. Clinical Cancer Research, 2004, 10, 2761-2765.	7.0	213

#	Article	IF	Citations
289	A Quantitative Promoter Methylation Profile of Prostate Cancer. Clinical Cancer Research, 2004, 10, 8472-8478.	7.0	234
290	Intraoperative Molecular Margin Analysis in Head and Neck Cancer. JAMA Otolaryngology, 2004, 130, 39.	1.2	116
291	Early Occurrence of <i>RASSF1A</i> Hypermethylation and Its Mutual Exclusion with <i>BRAF</i> Mutation in Thyroid Tumorigenesis. Cancer Research, 2004, 64, 1664-1668.	0.9	142
292	Real-Time Gap Ligase Chain Reaction. Clinical Cancer Research, 2004, 10, 2379-2385.	7.0	27
293	Detection of Promoter Hypermethylation of Multiple Genes in the Tumor and Bronchoalveolar Lavage of Patients with Lung Cancer. Clinical Cancer Research, 2004, 10, 2284-2288.	7.0	163
294	Altered Sumoylation of p63& alpha; Contributes to the Split-Hand/Foot Malformation Phenotype. Cell Cycle, 2004, 3, 1587-1596.	2.6	54
295	Quantitative Detection of Promoter Hypermethylation of Multiple Genes in the Tumor, Urine, and Serum DNA of Patients with Renal Cancer. Cancer Research, 2004, 64, 5511-5517.	0.9	218
296	Gene expression alterations over large chromosomal regions in cancers include multiple genes unrelated to malignant progression. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 8715-8720.	7.1	49
297	Optimal Use of a Panel of Methylation Markers with GSTP1 Hypermethylation in the Diagnosis of Prostate Adenocarcinoma. Clinical Cancer Research, 2004, 10, 5518-5522.	7.0	82
298	Detection of BRAF Mutation on Fine Needle Aspiration Biopsy Specimens: A New Diagnostic Tool for Papillary Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2867-2872.	3.6	239
299	CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nature Medicine, 2004, 10, 374-381.	30.7	79
300	BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Modern Pathology, 2004, 17, 1359-1363.	5.5	161
301	The V599E BRAF mutation is uncommon in biliary tract cancers. Modern Pathology, 2004, 17, 1386-1391.	5.5	40
302	Molecular markers of radiation effectiveness in head and neck squamous cell carcinoma. Seminars in Radiation Oncology, 2004, 14, 130-138.	2.2	10
303	Detection of LOH and Mitochondrial DNA Alterations in Ductal Lavage and Nipple Aspirate Fluids from High-risk Patients. Breast Cancer Research and Treatment, 2004, 84, 99-105.	2.5	49
304	Aquaporin expression in human lymphocytes and dendritic cells. American Journal of Hematology, 2004, 75, 128-133.	4.1	76
305	Use of single nucleotide polymorphism arrays to identify a novel region of loss on chromosome 6q in squamous cell carcinomas of the oral cavity. Head and Neck, 2004, 26, 345-352.	2.0	16
306	Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head and Neck, 2004, 26, 870-877.	2.0	44

#	Article	IF	Citations
307	Genetic and Epigenetic screening for gene alterations of the chromatin-remodeling factor, SMARCA4/BRG1, in lung tumors. Genes Chromosomes and Cancer, 2004, 41, 170-177.	2.8	103
308	Microsatellite analysis of serum DNA in patients with head and neck cancer. International Journal of Cancer, 2004, 111, 96-100.	5.1	33
309	QUANTITATIVE GSTP1 METHYLATION LEVELS CORRELATE WITH GLEASON GRADE AND TUMOR VOLUME IN PROSTATE NEEDLE BIOPSIES. Journal of Urology, 2004, 171, 2195-2198.	0.4	48
310	Uses of DNA Methylation in Cancer Diagnosis and Risk Assessment. , 2004, , 11-26.		5
311	Detecting Cervical Cancer by Quantitative Promoter Hypermethylation Assay on Cervical Scrapings: A Feasibility Study. Molecular Cancer Research, 2004, 2, 289-295.	3.4	47
312	Response to ?MMTV-related env sequences in human breast tumors?. International Journal of Cancer, 2003, 106, 139-139.	5.1	1
313	Spindle assembly checkpoint defects and chromosomal instability in head and neck squamous cell carcinoma. International Journal of Cancer, 2003, 107, 46-52.	5.1	28
314	Mitochondrial DNA alterations in thyroid cancer. Journal of Surgical Oncology, 2003, 82, 170-173.	1.7	33
315	Biallelic inactivation of the RIZ1 gene in human gastric cancer. Oncogene, 2003, 22, 6954-6958.	5.9	52
316	Involvement of aquaporins in colorectal carcinogenesis. Oncogene, 2003, 22, 6699-6703.	5.9	175
317	Molecular Analysis of Peritoneal Fluid in Ovarian Cancer Patients. Modern Pathology, 2003, 16, 636-640.	5.5	17
318	Proteomic analysis of cancer-cell mitochondria. Nature Reviews Cancer, 2003, 3, 789-795.	28.4	95
319	Quantitative Gstp1 Methylation Clearly Distinguishes Benign Prostatic Tissue And Limited Prostate Adenocarcinoma. Journal of Urology, 2003, 169, 1138-1142.	0.4	135
320	p53 Mutations and Survival in Stage I Non-Small-Cell Lung Cancer: Results of a Prospective Study. Journal of the National Cancer Institute, 2003, 95, 961-970.	6.3	196
321	BRAF Mutation in Papillary Thyroid Carcinoma. Journal of the National Cancer Institute, 2003, 95, 625-627.	6.3	849
322	PUMA in head and neck cancer. Cancer Letters, 2003, 199, 75-81.	7.2	33
323	Serum Protein MALDI Profiling to Distinguish Upper Aerodigestive Tract Cancer Patients From Control Subjects. Journal of the National Cancer Institute, 2003, 95, 1711-1717.	6.3	68
324	Lack of BRAF Mutation in Primary Uveal Melanoma. , 2003, 44, 2876.		117

#	Article	IF	Citations
325	Quantitative GSTP1 Methylation and the Detection of Prostate Adenocarcinoma in Sextant Biopsies. Journal of the National Cancer Institute, 2003, 95, 1634-1637.	6.3	110
326	Re: Is TIG1 a New Tumor Suppressor in Prostate Cancer?. Journal of the National Cancer Institute, 2003, 95, 919-920.	6.3	17
327	p63α Mutations Lead to Aberrant Splicing of Keratinocyte Growth Factor Receptor in the Hay-Wells Syndrome. Journal of Biological Chemistry, 2003, 278, 23906-23914.	3.4	79
328	Electrophile and oxidant damage of mitochondrial DNA leading to rapid evolution of homoplasmic mutations. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 1838-1843.	7.1	164
329	Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma. Journal of the National Cancer Institute, 2003, 95, 484-486.	6.3	762
330	Molecular Detection of Head and Neck Cancer., 2003,, 305-IV.		0
331	Reply to "Proteomic alterations of cancer-cell mitochondria: driver or bystander?― Nature Reviews Cancer, 2003, 3, 796-796.	28.4	0
332	Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clinical Cancer Research, 2003, 9, 1370-5.	7.0	120
333	Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Research, 2003, 63, 2216-22.	0.9	122
334	Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Research, 2003, 63, 2316-21.	0.9	107
335	DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Research, 2003, 63, 2351-7.	0.9	184
336	The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clinical Cancer Research, 2003, 9, 2981-4.	7.0	61
337	A transcriptional progression model for head and neck cancer. Clinical Cancer Research, 2003, 9, 3058-64.	7.0	103
338	Epigenetic inactivation of RASSF1A in head and neck cancer. Clinical Cancer Research, 2003, 9, 3635-40.	7.0	75
339	High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single-nucleotide polymorphism array. Cancer Research, 2003, 63, 5723-6.	0.9	44
340	A tumor-suppressive role for trypsin in human cancer progression. Cancer Research, 2003, 63, 6575-8.	0.9	62
341	Death-associated protein kinase promoter hypermethylation in normal human lymphocytes. Cancer Research, 2003, 63, 7694-8.	0.9	37
342	Identification of mtDNA Mutations in Human Cancer. , 2002, 197, 107-117.		13

#	Article	IF	CITATIONS
343	Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology, 2002, 60, 1131-1135.	1.0	196
344	Molecular assessment of lymph nodes in patients with resected stage I non–small cell lung cancer: Preliminary results of a prospective study. Journal of Thoracic and Cardiovascular Surgery, 2002, 123, 466-474.	0.8	56
345	î"Np63 induces î²-catenin nuclear accumulation and signaling. Cancer Cell, 2002, 1, 369-379.	16.8	197
346	Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell, 2002, 2, 485-495.	16.8	315
347	Progression of microsatellite instability from premalignant lesions to tumors of the head and neck. International Journal of Cancer, 2002, 102, 615-617.	5.1	43
348	Interaction and colocalization of PGP9.5 with JAB1 and p27Kip1. Oncogene, 2002, 21, 3003-3010.	5.9	105
349	Molecular detection approaches for smoking associated tumors. Oncogene, 2002, 21, 7289-7297.	5.9	64
350	Emerging molecular markers of cancer. Nature Reviews Cancer, 2002, 2, 210-219.	28.4	590
351	Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Research, 2002, 62, 371-5.	0.9	240
352	Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clinical Cancer Research, 2002, 8, 481-7.	7.0	119
353	Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clinical Cancer Research, 2002, 8, 1203-9.	7.0	105
354	Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Research, 2002, 62, 3659-62.	0.9	462
355	Mitochondrial C-tract alteration in premalignant lesions of the head and neck: a marker for progression and clonal proliferation. Clinical Cancer Research, 2002, 8, 2260-5.	7.0	89
356	p16(MTS-1/CDKN2/INK4a) in Cancer Progression. Experimental Cell Research, 2001, 264, 42-55.	2.6	415
357	Head and Neck Cancer. New England Journal of Medicine, 2001, 345, 1890-1900.	27.0	1,176
358	Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Letters, 2001, 170, 73-79.	7.2	37
359	Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer, 2001, 92, 1525-1530.	4.1	381
360	Microsatellite instability at AAAG repeat sequences in respiratory tract cancers. International Journal of Cancer, 2001, 91, 200-204.	5.1	55

#	Article	IF	Citations
361	Molecular detection of cervical intraepithelial neoplasia and cervical carcinoma by microsatellite analysis of Papanicolaou smears. International Journal of Cancer, 2001, 93, 424-429.	5.1	15
362	Loss of chromosome arms 3p and 9p and inactivation of P16INK4a in normal epithelium of patients with primary lung cancer. Genes Chromosomes and Cancer, 2001, 32, 119-125.	2.8	18
363	Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene, 2001, 20, 3528-3532.	5.9	132
364	Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene, 2001, 20, 5195-5198.	5.9	220
365	Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung., 2001, 92, 1525.		1
366	Genetic Alterations in Urinary Bladder Carcinosarcoma: Evidence of a Common Clonal Origin. European Urology, 2000, 37, 350-357.	1.9	54
367	Predominance of brain tumors in an extended Li-Fraumeni (SBLA) kindred, including a case of Sturge-Weber syndrome., 2000, 88, 433-439.		21
368	Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. International Journal of Cancer, 2000, 86, 684-689.	5.1	106
369	Molecular analysis of the candidate tumor suppressor geneING1 in human head and neck tumors with 13q deletions., 2000, 27, 319-322.		37
370	Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. International Journal of Cancer, 2000, 89, 514-518.	5.1	88
371	p53 overexpression and K- ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 2000, 7, 426-431.	2.0	61
372	Two Distinct Regions of Loss on Chromosome Arm 4q in Primary Head and Neck Squamous Cell Carcinoma. JAMA Otolaryngology, 2000, 126, 1073.	1.2	18
373	Loss of Heterozygosity Assay for Molecular Detection of Cancer Using Energy-transfer Primers and Capillary Array Electrophoresis. Genome Research, 2000, 10, 1211-1218.	5.5	49
374	Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers. Journal of the National Cancer Institute, 2000, 92, 709-720.	6.3	2,586
375	Facile Detection of Mitochondrial DNA Mutations in Tumors and Bodily Fluids. Science, 2000, 287, 2017-2019.	12.6	767
376	Circulating DNA: What We Know and What We Need to Learn. Annals of the New York Academy of Sciences, 2000, 906, 1-4.	3.8	36
377	An Overview on the Isolation and Analysis of Circulating Tumor DNA in Plasma and Serum. Annals of the New York Academy of Sciences, 2000, 906, 8-12.	3.8	104
378	Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. International Journal of Cancer, 2000, 89, 514-518.	5.1	3

#	Article	IF	Citations
379	The Potential of Molecular Screening. Surgical Oncology Clinics of North America, 1999, 8, 641-656.	1.5	17
380	Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer. Oncogene, 1999, 18, 5843-5849.	5.9	113
381	Head and Neck Cancer in CNonsmokers: A Distinct Clinical and Molecular Entity. Laryngoscope, 1999, 109, 1544-1551. Molecular methods for the diagnosis of cancer1Oncor, Inc. provided research funding for the study	2.0	216
382	described in this paper. Under an agreement between Oncor and the Johns Hopkins University, Dr. Sidransky is entitled to a share of sales royalty received by the University from Oncor. Under that agreement, the University and Dr. Sidransky also have received Oncor stock which, under University policy, cannot be traded until two years after the first commercial sales of the products related to	7.4	22
383	this research. The. Biochimica Et Biophysica Acta: Reviews on Cancer, 1999, 1423, C11-C18. Absence of intragenic mismatch mutations in small cell lung cancers with microsatellite instability., 1999, 80, 944-945.		1
384	Mutation analysis of hBUB1 in aneuploid HNSCC and lung cancer cell lines. Cancer Letters, 1999, 139, 183-187.	7.2	61
385	Immunohistochemical detection of p53 protein accumulation in head and neck cancer: Correlation with p53 gene alterations. Human Pathology, 1999, 30, 1221-1225.	2.0	90
386	Comparative microsatellite analysis in discerning origin of disseminated tumor: The case of a patient with malignant ascites and a history of multiple tumors. Human Pathology, 1999, 30, 1111-1113.	2.0	3
387	PGP9.5 As a Candidate Tumor Marker for Non-Small-Cell Lung Cancer. American Journal of Pathology, 1999, 155, 711-715.	3.8	160
388	Chromosome 9p21 Loss and p16 Inactivation in Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma. Journal of Surgical Research, 1999, 84, 88-93.	1.6	83
389	Absence of TSG101 transcript abnormalities in human cancers. Oncogene, 1998, 16, 2815-2818.	5.9	12
390	Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene, 1998, 16, 3215-3218.	5.9	175
391	A new human p53 homologue. Nature Medicine, 1998, 4, 747-748.	30.7	235
392	Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors., 1998, 23, 239-243.		117
393	Lack of BRCA2 alterations in primary head and neck squamous cell carcinoma. Otolaryngology - Head and Neck Surgery, 1998, 119, 21-25.	1.9	16
394	MICROSATELLITE DEOXYRIBONUCLEIC ACID ANALYSIS TO DETECT BLADDER CANCER IN BLADDER EXSTROPHY. Journal of Urology, 1998, 160, 2192-2193.	0.4	3
395	Degenerate Oligonucleotide-Primed PCR (DOPPCR): Evaluation of its Reliability for Screening of Genetic Alterations in Neoplasia. BioTechniques, 1998, 25, 1036-1038.	1.8	17
396	Functional analysis of wild-type and malignant glioma derived CDKN2A \hat{l}^2 alleles: Evidence for an RB-independent growth suppressive pathway. Oncogene, 1997, 15, 2013-2020.	5.9	33

#	Article	IF	CITATIONS
397	Detection of bladder cancer recurrence by microsatellite analysis of urine. Nature Medicine, 1997, 3, 621-624.	30.7	248
398	Microsatellite-based cancer detection using capillary array electrophoresis and energy-transfer fluorescent primers. Electrophoresis, 1997, 18, 1742-1749.	2.4	73
399	Genetic markers for early detection of lung cancer and outcome measures for response to chemoprevention. Journal of Cellular Biochemistry, 1997, 67, 64-73.	2.6	14
400	Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes and Cancer, 1997, 19, 90-96.	2.8	169
401	Detailed deletion mapping at chromosome 9p21 in non-small cell lung cancer by microsatellite analysis and fluorescencein situ hybridization., 1997, 74, 588-592.		33
402	Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients., 1997, 74, 625-629.		58
403	Detailed deletion mapping at chromosome 9p21 in nonâ€small cell lung cancer by microsatellite analysis and fluorescence in situ hybridization. International Journal of Cancer, 1997, 74, 588-592.	5.1	2
404	Germline Translocation t(5;20)(p15;q11) and Familial Transitional Cell Carcinoma. Journal of Urology, 1996, 155, 1035-1036.	0.4	22
405	CLINICAL IMPLICATIONS OF THE p53 GENE. Annual Review of Medicine, 1996, 47, 285-301.	12.2	168
406	Molecular analysis of effectiveness of Mohs' surgical technique. Lancet, The, 1996, 347, 1692-1693.	13.7	2
407	Cancer genetics: Two tracks but one race?. Current Biology, 1996, 6, 523-525.	3.9	14
408	An allelotype of papillary thyroid cancer. , 1996, 69, 442-444.		34
409	Molecular staging of head and neck squamous carcinoma. Cancer and Metastasis Reviews, 1996, 15, 3-10.	5.9	44
410	Is human patched the gatekeeper of common skin cancers?. Nature Genetics, 1996, 14, 7-8.	21.4	69
411	Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Medicine, 1996, 2, 1035-1037.	30.7	570
412	Molecular genetics of head and neck cancer. Current Opinion in Oncology, 1995, 7, 229-233.	2.4	94
413	Molecular markers in cancer: Can we make better predictions?. International Journal of Cancer, 1995, 64, 1-2.	5.1	29
414	Frequent Loss of Chromosome Arms 8p and 13q in Collecting Duct Carcinoma (CDC) of the Kidney. Genes Chromosomes and Cancer, 1995, 12, 76-80.	2.8	75

#	Article	IF	CITATIONS
415	Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genetics, 1995, 11, 210-212.	21.4	593
416	$5\hat{a}$ €2 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine, 1995, 1, 686-692.	30.7	1,812
417	Molecular Assessment of Histopathological Staging in Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 1995, 332, 429-435.	27.0	690
418	Association between Cigarette Smoking and Mutation of the p53 Gene in Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 1995, 332, 712-717.	27.0	578
419	Molecular Biology and the Early Detection of Carcinoma of the Bladder The Case of Hubert H. Humphrey. New England Journal of Medicine, 1994, 330, 1276-1278.	27.0	70
420	Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. American Journal of Surgery, 1994, 168, 429-432.	1.8	121
421	RET proto-oncogene mutations in inherited and sporadic medullary thyroid cancer. Human Molecular Genetics, 1994, 3, 1895-1897.	2.9	94
422	Oncogene mutations as intermediate markers. Journal of Cellular Biochemistry, 1993, 53, 184-187.	2.6	4
423	Clonal Origin of Bladder Cancer. New England Journal of Medicine, 1992, 326, 737-740.	27.0	496
424	Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature, 1992, 355, 846-847.	27.8	628
425	Colon cancer genetics. Cancer, 1992, 70, 1300-1312.	4.1	51
426	MOLECULAR GENETICS AND BIOCHEMICAL MECHANISMS IN BLADDER CANCER. Urologic Clinics of North America, 1992, 19, 629-639.	1.8	48
427	Interaction and colocalization of PGP9.5 with JAB1 and p27Kip1., 0, .		2